ClinicalTrials.gov URL
COVID-19 Information
- Gimsilumab is a monoclonal antibody that targets GM-CSF, a pro-inflammatory cytokine found to be up-regulated in COVID-19 patients
- Emerging clinical evidence in COVID-19 patients suggests that GM-CSF contributes to immunopathology caused by SARS CoV-2 in patients with or at risk of developing ARDS
- ARDS is a serious complication of COVID-19 which necessitates hospitalization and mechanical ventilation or other life support measures
- A Phase 1 study of gimsilumab conducted by Roivant completed dosing last month following extensive non-clinical research; gimsilumab treatment has been associated with a favorable safety and tolerability profile to date
Stage
Phase 1
Company Type
Late Onset Intervention